Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events) "CANTOS"

Active, not recruiting

Phase 3 Results N/A

Summary of Purpose

Main Study (CACZ885M2301): The purpose of the pivotal phase of this trial is to test the hypothesis that canakinumab treatment of patients with MI at least one month prior to study entry and elevated hsCRP will prevent recurrent cardiovascular events. The purpose of the extension phase of the main study is to collect additional long-term safety data on continued exposure to canakinumab in patients who...

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 19 March 2018.

11 Apr 2011 29 Mar 2011 28 Mar 2017 2 Mar 2020 1 Mar 2018 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Design

  • Allocation: Randomized
  • Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
  • Purpose: Treatment
  • Endpoint: Safety/Efficacy Study
  • Intervention: Parallel Assignment


  • Novartis Pharmaceuticals